Clinical Trial Update: This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. [Phase 1, Phase 2]

View source ↗

Summary

This Phase I/II open-label trial evaluates an anti-CD19/CD22 CAR-T cell therapy in adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• Anti-CD19/CD22 CAR-T cell therapy (CAR-T cell therapy targeting CD19 and CD22)

Snippet

Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Conditions: Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING